PODD
Insulet Corporation
NASDAQ · Healthcare · Medical - Devices · US
$147.48
−2.06%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.1B | 2.7B | 2.1B | 1.7B | 1.3B |
| Cost of Revenue | 883.1M | 768.2M | 625.9M | 537.2M | 499.7M |
| Gross Profit | 2.2B | 1.9B | 1.4B | 1.2B | 805.6M |
| Operating Expenses | |||||
| R&D Expense | 345.9M | 301.1M | 219.6M | 205.0M | 180.2M |
| SG&A Expense | 1.3B | 1.2B | 917.2M | 734.9M | 587.8M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.7B | 1.5B | 1.1B | 939.9M | 768.0M |
| Cost and Expenses | 2.5B | 2.2B | 1.8B | 1.5B | 1.3B |
| Operating Income (EBIT) | 515.8M | 473.8M | 308.9M | 220.0M | 37.6M |
| Non-Operating | |||||
| Interest Income | 22.8M | 34.7M | 39.5M | 28.6M | 9.3M |
| Interest Expense | 63.4M | 79.7M | 42.7M | 36.2M | 36.0M |
| Net Interest Income | (40.6M) | (45.0M) | (3.2M) | (7.6M) | (26.7M) |
| Other Non-Op Income/Expense | (21.1M) | (134.3M) | (8.7M) | (5.4M) | (27.8M) |
| Non-Operating Income (excl Interest) | (42.3M) | 54.6M | (34.0M) | (30.8M) | (8.2M) |
| EBT (Pre-Tax Income) | 494.7M | 339.5M | 300.2M | 214.6M | 9.8M |
| Income Tax Expense | 119.3M | 92.4M | (118.1M) | 8.3M | 5.2M |
| Bottom Line | |||||
| Net Income | 375.3M | 247.1M | 418.3M | 206.3M | 4.6M |
| Earnings from Cont. Ops | 375.3M | 247.1M | 418.3M | 206.3M | 4.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 375.5M | 247.1M | 418.3M | 206.3M | 4.6M |
| Per Share | |||||
| Basic EPS | $5.36 | $3.51 | $5.97 | $2.96 | $0.07 |
| Diluted EPS | $5.35 | $3.48 | $5.78 | $2.94 | $0.07 |
| Revenue Per Share | $44.06 | $38.50 | $29.56 | $24.33 | $18.82 |
| Shares | |||||
| Basic Shares Outstanding | 69.3M | 70.3M | 70.1M | 69.8M | 69.4M |
| Diluted Shares Outstanding | 69.4M | 71.9M | 73.9M | 73.6M | 69.9M |
| Profitability Metrics | |||||
| EBITDA | 636.9M | 532.3M | 423.7M | 323.6M | 109.0M |
| D&A | 78.8M | 113.1M | 80.8M | 72.8M | 63.2M |
| EBIT | 558.1M | 419.2M | 342.9M | 250.8M | 45.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026